FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:472-482 February 2, 2006 Number 5 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Davis, J. M. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background The treatment of schizophrenia with multiple antipsychotic drugs is common, but the benefits and risks are not known.

Methods In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to receive eight weeks of daily augmentation with 3 mg of risperidone or with placebo. This course of treatment was followed by an optional 18 weeks of augmentation with risperidone. The primary outcome was reduction in the total score for severity of symptoms on the Positive and Negative Syndrome Scale (PANSS). The secondary outcomes included cognitive functioning.

Results A total of 68 patients were randomly assigned to treatment. In the double-blind phase, the mean total score for the severity of symptoms decreased from baseline to eight weeks in both the risperidone and the placebo groups. There was no statistically significant difference in symptomatic benefit between augmentation with risperidone and placebo: 9 of 34 patients receiving placebo and 6 of 34 receiving risperidone responded to treatment (P=0.38). The mean difference in the change in PANSS scores from baseline to eight weeks between those receiving risperidone and those receiving placebo was 0.1 (95 percent confidence interval, –7.3 to 7.0). The verbal working-memory index showed a small decline in the risperidone group and a small improvement in the placebo group (P=0.02 for the comparison between the two groups in the change from baseline). The increase in fasting blood glucose levels was mildly greater in the risperidone group than in the placebo group (16.2 vs. 1.8 mg per deciliter [0.90 vs. 0.10 mmol per liter], P=0.04). The incidence and severity of other side effects did not differ between the two groups.

Conclusions In this short-term study, the addition of risperidone to clozapine did not improve symptoms in patients with severe schizophrenia. (ClinicalTrials.gov number, NCT00272584 [ClinicalTrials.gov] )

Source Information

From the Department of Psychiatry (W.G.H., R.W., G.W.M.) and the Division of Pharmaceutics and Biopharmaceutics (K.W.), University of British Columbia, Vancouver, Canada; Department of Psychology, Simon Fraser University, Burnaby, B.C., Canada (A.E.T.); Department of Psychiatry, University of Hong Kong, Hong Kong, China (E.Y.H.C.); Department of Psychology, Sun Yat-Sen University, Guangzhou, China (R.C.K.C.); Castle Peak Hospital, Hong Kong, China (J.O.Y.W.); Department of Psychiatry, Saarland University, Homburg, Germany (A.B., P.F.), Department of Psychiatry, University of Cambridge, Cambridge, United Kingdom (E.P.-C., P.J.M.); Department of Psychiatry, University of Montreal, Montreal (E.S.); and Riverview Hospital, Port Coquitlam, B.C., Canada (R.P.).

Address reprint requests to Dr. Honer at the Centre for Complex Disorders and the Department of Psychiatry, University of British Columbia, Vancouver General Hospital Research Pavilion, 828 W. 10th Ave., Suite 211, Vancouver, BC V5Z 1L8, Canada, or at honer{at}interchange.ubc.ca.

Full Text of this Article

Related Letters:

Clozapine Alone versus Clozapine and Risperidone for Refractory Schizophrenia
Grass G., Hellmich M., Leweke F. M., Meltzer H. Y., Yacolu A. E. A., Akdede B. B. K., Gerson S. L., Honer W. G., Thornton A. E., MacEwan G. W., Davis J. M.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:1846-1848, Apr 27, 2006. Correspondence

This article has been cited by other articles:

• Langan, J., Shajahan, P. (2010). Antipsychotic polypharmacy: review of mechanisms, mortality and management. The Psychiatrist 34: 58-62 [Abstract] [Full Text]  
• Mojtabai, R., Olfson, M. (2010). National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry. Arch Gen Psychiatry 67: 26-36 [Abstract] [Full Text]  
• Obermeier, M., Mayr, A., Schennach-Wolff, R., Seemuller, F., Moller, H.-J., Riedel, M. (2009). Should the PANSS Be Rescaled?. Schizophr Bull 0: sbp124v1-sbp124 [Abstract] [Full Text]  
• Zink, M, Kuwilsky, A, Krumm, B, Dressing, H (2009). Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol 23: 305-314 [Abstract]  
• Wang, P. S., Ulbricht, C. M., Schoenbaum, M. (2009). Improving Mental Health Treatments Through Comparative Effectiveness Research. Health Aff (Millwood) 28: 783-791 [Abstract] [Full Text]  
• Correll, C. U., Rummel-Kluge, C., Corves, C., Kane, J. M., Leucht, S. (2009). Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials. Schizophr Bull 35: 443-457 [Abstract] [Full Text]  
• Barbui, C., Signoretti, A., Mule, S., Boso, M., Cipriani, A. (2009). Does the Addition of a Second Antipsychotic Drug Improve Clozapine Treatment?. Schizophr Bull 35: 458-468 [Abstract] [Full Text]  
• Wheeler, A. J (2008). Treatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand. The Annals of Pharmacotherapy 42: 852-860 [Abstract] [Full Text]  
• Hill, S. K., Reilly, J. L., Harris, M. S. H., Khine, T., Sweeney, J. A. (2008). Oculomotor and Neuropsychological Effects of Antipsychotic Treatment for Schizophrenia. Schizophr Bull 34: 494-506 [Abstract] [Full Text]  
• (2008). Bibliography Schizophrenia. Focus 6: 197-199 [Full Text]  
• (2008). Abstracts. Focus 6: 200-204 [Full Text]  
• HAZRA, M., MAMO, D. C., REMINGTON, G. (2008). Adjunctive Versus Monotherapeutic Treatment for Schizophrenia: Addressing Antipsychotic Side Effects. Am. J. Psychiatry 165: 396-397 [Full Text]  
• Kane, J. M., Leucht, S. (2008). Unanswered Questions in Schizophrenia Clinical Trials. Schizophr Bull 34: 302-309 [Full Text]  
• Kreyenbuhl, J., Olfson, M., Marcus, S. C. (2007). Adding and Switching Antipsychotics: In Reply. Psychiatr. Serv. 58: 1375-1376 [Full Text]  
• Kreyenbuhl, J., Marcus, S. C., West, J. C., Wilk, J., Olfson, M. (2007). Adding or Switching Antipsychotic Medications in Treatment-Refractory Schizophrenia. Psychiatr. Serv. 58: 983-990 [Abstract] [Full Text]  
• Gilmer, T. P., Dolder, C. R., Folsom, D. P., Mastin, W., Jeste, D. V. (2007). Antipsychotic Polypharmacy Trends Among Medi-Cal Beneficiaries With Schizophrenia in San Diego County, 1999-2004. Psychiatr. Serv. 58: 1007-1010 [Abstract] [Full Text]  
• Kreyenbuhl, J. A., Valenstein, M., McCarthy, J. F., Ganoczy, D., Blow, F. C. (2007). Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns. Psychiatr. Serv. 58: 489-495 [Abstract] [Full Text]  
• Ahmed, M., Osser, D. N, Boisvert, C. M, Albert, L. G, Aslam, M. (2007). Rationale for Emphasis on Management over Treatment of Schizophrenia in Clinical Practice. The Annals of Pharmacotherapy 41: 693-695 [Abstract] [Full Text]  
• (2006). Other articles noted. Evid. Based Med. 11: 95-96 [Full Text]  
• Grass, G., Hellmich, M., Leweke, F. M., Meltzer, H. Y., Yagcioglu, A. E. A., Akdede, B. B. K., Gerson, S. L., Honer, W. G., Thornton, A. E., MacEwan, G. W., Davis, J. M. (2006). Clozapine alone versus clozapine and risperidone for refractory schizophrenia.. NEJM 354: 1846-1848 [Full Text]  
• Tonks, A. (2006). What's new in the other general journals. BMJ 332: 351-352 [Full Text]  
• Davis, J. M. (2006). The Choice of Drugs for Schizophrenia. NEJM 354: 518-520 [Full Text]